PATENT CLAIM ANALYSIS

Application Number: 15918195
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "210210"]

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

Claim (Index 8):
The compound of  claim 7 , wherein: is selected from the group consisting of: R 3a  is independently selected from the group consisting of: H, F, Cl, CN, CO 2 H, \u2014CO 2 Me, \u2014CO 2 Et, \u2014CO 2 (i-Pr), \u2014CO 2 (t-Bu), \u2014CO 2 (n-Bu), \u2014CO 2 (i-Bu), \u2014CO 2 (CH 2 ) 2 OMe, \u2014CO 2 CH 2 CON(Me) 2 , \u2014NHCO 2 Me, \u2014CO 2 CH 2 (phenyl), \u2014CO 2 (C 3-6  cycloalkyl), and \u2014CO 2 (CH 2 ) 2 -triazole; and R 6  is selected from the group consisting of: H, C 1-4  alkyl, \u2014CO 2 (C 1-4  alkyl), \u2014CO(C 1-4  alkyl), \u2014COCH 2 N(C 1-4  alkyl) 2 , \u2014(CH 2 ) 1-2 N(C 1-4  alkyl) 2 , \u2014CONH(C 1-4  alkyl), \u2014CONH\u2014C 1-4  alkylene-O(C 1-4  alkyl), \u2014CONH\u2014C 1-4  alkylene-N(C 1-4  alkyl) 2 , \u2014CONH\u2014C 1-4  alkylene-CO 2 (C 1-4  alkyl), \u2014CH 2 Ph, and \u2014CO 2 \u2014C 1-4  alkylene-Ph.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 90.0
- Lexical Diversity: 1.17949
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14117513', '15361589', '14617979', '14886415', '14350411']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8658759604090981
- 35 USC 102 Novelty (BERT): 0.6418323421092992
- Combined Prediction Score: 0.8434715985791181
- Mean Citation Score: 542.883702
- Max Citation Score: 635.02765
- Similarity Product: 576.5627843871176

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test